A Randomized Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects

Trial Profile

A Randomized Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Bromfenac (Primary)
  • Indications Ocular inflammation; Ocular pain
  • Focus Registrational; Therapeutic Use
  • Sponsors InSite Vision
  • Most Recent Events

    • 09 Apr 2016 According to Sun Pharmaceutical Industries media release, the US FDA has approved a New Drug Application (NDA) for BromSite for the treatment of inflammation and prevention of pain in cataract surgery.
    • 17 Aug 2015 According to InSite Vision media release, the US FDA has accepted for review a New Drug Application (NDA) for BromSite for the treatment of inflammation and prevention of pain in cataract surgery.
    • 11 Jun 2015 According to InSite Vision media release, the company has completed the submission of New Drug Application (NDA) to the US FDA for the treatment of inflammation and prevention of pain in cataract surgery.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top